Abstract
A 54-year-old woman presents to the emergency department because of altered mental status. She has a history of hypertension and breast cancer and weighs 65 kg. The patient has no prior history of transfusion. Her laboratory values are significant for a hematocrit (Hct) level of 20%, platelets 12 K/μL, lactate dehydrogenase (LDH) level 2500 U/L, and creatinine 2.3 mg/dL. The prothrombin time (PT) and activated partial thromboplastin time (aPTT) laboratory values are within the normal range. A type and screen sample (ethylenediaminetetraacetic acid [EDTA] anticoagulant) is submitted to the blood bank along with a request for two units of red blood cells (RBCs). In addition, urgent therapeutic plasma exchange (TPE) is requested.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169–81.
Soliris® Prescribing Information. Alexion Pharmaceuticals, Inc., New Haven, CT. October 2017.
Recommended Reading
Davenport RD. Therapeutic apheresis. In: Fung MK, Grossman BJ, Hillyer CD, Westhoff CM, editors. Technical manual. 18th ed. Bethesda: AABB; 2014. p. 645–61.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Friedman, M.T., West, K.A., Bizargity, P., Annen, K., Jhang, J.S. (2018). Time to Change the Plasma. In: Immunohematology and Transfusion Medicine. Springer, Cham. https://doi.org/10.1007/978-3-319-90960-8_47
Download citation
DOI: https://doi.org/10.1007/978-3-319-90960-8_47
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-90959-2
Online ISBN: 978-3-319-90960-8
eBook Packages: MedicineMedicine (R0)